Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

1.0K
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
1.0K
Dysrhythmias II: Classification of Tachyarrhythmias01:28

Dysrhythmias II: Classification of Tachyarrhythmias

788
Tachyarrhythmias are a type of dysrhythmia where the heart rate exceeds 100 beats per minute. Here are some common types of tachyarrhythmias:Sinus TachycardiaSinus tachycardia originates from increased impulses from the sinus node, leading to an elevated heart rate. It is often triggered by stress, fever, or exercise.Patients may experience palpitations, a sensation of a racing heart, dizziness, and chest discomfort.Causes and Risk Factors: Common causes include physical exertion, emotional...
788
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.2K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

4.1K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
4.1K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Characteristics, Healthcare Resource Utilization, and Costs of Patients with Generalized Pustular Psoriasis in Taiwan: A National Claims Database Study.

Psoriasis (Auckland, N.Z.)·2026
Same author

Response to "Comment on 'recent trends of LDL-C control and lipid-lowering therapy in patients with ASCVD in Taiwan: 2015-2020".

Journal of the Formosan Medical Association = Taiwan yi zhi·2026
Same author

Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same author

Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same author

ASSOCIATION BETWEEN INTRODUCTION OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE AND BURDEN OF HOSPITALIZED ADULT PNEUMOCOCCAL DISEASE IN TAIWAN - A RETROSPECTIVE DATABASE STUDY.

Epidemiology and infection·2026
Same author

Comparative evaluation of open-access Bayesian calculators for vancomycin area under the concentration-time curve estimation in non-critically ill hospitalized adults in Taiwan.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy·2026

Related Experiment Video

Updated: Apr 10, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.3K

Ventricular Arrhythmia and Sudden Death Risk With Concomitant Antipsychotic and SSRI Use.

Hsiu-Ting Chien1,2, Shu-Wen Lin1,3,4, Te-Jung Kung1

  • 1Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.

JAMA Network Open
|April 9, 2026
PubMed
Summary
This summary is machine-generated.

Concurrent use of antipsychotics and selective serotonin reuptake inhibitors (SSRIs) increases the risk of ventricular arrhythmia or sudden death. This study found a significant association, highlighting the need for careful prescribing practices.

More Related Videos

Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits
06:46

Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits

Published on: February 28, 2025

903
Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits
10:25

Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits

Published on: March 27, 2021

6.8K

Related Experiment Videos

Last Updated: Apr 10, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.3K
Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits
06:46

Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits

Published on: February 28, 2025

903
Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits
10:25

Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits

Published on: March 27, 2021

6.8K

Area of Science:

  • Cardiology
  • Psychiatry
  • Pharmacology

Background:

  • Antipsychotics and SSRIs are independently linked to increased risk of ventricular arrhythmia and sudden cardiac death.
  • Limited clinical data exist on the combined risk associated with concurrent use of these medication classes.

Purpose of the Study:

  • To evaluate the association between concurrent antipsychotic and SSRI use and the risk of ventricular arrhythmia or sudden death.
  • To assess the safety of co-prescribing these medications in adult patients.

Main Methods:

  • A sequential target trial emulation using US and Taiwan insurance claims data (2010-2023).
  • Weekly assessment of SSRI initiation in adult patients starting antipsychotics over 52 weeks.
  • Inverse probability weighting and adjustment for time-varying covariates were applied.

Main Results:

  • The study included over 300,000 US patients and 191,000 Taiwanese patients.
  • SSRI initiation in antipsychotic users was associated with a significantly increased risk of ventricular arrhythmia or sudden death (HRs ranging from 1.51 to 3.32 across cohorts).
  • Specific SSRIs like citalopram and escitalopram showed higher associated risks.

Conclusions:

  • Concurrent use of antipsychotics and SSRIs is associated with an elevated risk of ventricular arrhythmia or sudden death.
  • Healthcare providers should exercise caution when prescribing these medications together.
  • Further research may be warranted to elucidate specific risk factors and management strategies.